Intrinsic value of Stericycle - SRCL

Previous Close

$76.88

  Intrinsic Value

premium content

  Rating & Target

premium content

  Value-price divergence*

premium content

Previous close

$76.88

 
Intrinsic value premium content
 
Up/down potential premium content
 
Rating premium content
 
Value-price divergence* premium content

Premium access subscription - $499/yr

please register and log in before paying

*Intrinsic value change (in %) minus stock price change (in %) in the past 12 months.

We calculate the intrinsic value of SRCL stock by summing up the current values of future distributable cash flows generated by the company and dividing the sum by the number of outstanding shares. As such, the intrinsic value calculation depends entirely on projections. The more accurate your projections of the company's performance are - the more reliable is the intrinsic value calculation result. Please make sure to check the stock valuation input data below and adjust it if necessary. The quality of the output (intrinsic valuation result) is only as good as the quality of the input. See also DISCLAIMERS.

STOCK VALUATION INPUT DATA

Revenue (in 2016), $M
Initial revenue growth rate, %
Terminal revenue growth rate, %
Revenue decline factor
Initial discount rate, %
Discount rate multiplier
Variable cost ratio, %
Fixed operating expenses, $M
Interest rate on debt, %
Effective corporate tax rate, %
Production assets / Revenue, %
Life of production assets, yrs
Working capital / Revenue, %
Revenue / Adjusted assets
Adjusted equity ratio
Cash flow adjustment, % of Revenue
Book value of equity, $M
Shares outstanding, mln
Market capitalization, $bln 6.5

 

FINANCIAL STATEMENTS FORECAST and PRESENT VALUE CALCULATION

Fiscal year
2016(a)
   2017
   2018
   2019
   2020
   2021
   2022
   2023
   2024
   2025
   2026
   2027
   2028
   2029
   2030
   2031
   2032
   2033
   2034
   2035
   2036
   2037
   2038
   2039
   2040
   2041
   2042
   2043
   2044
   2045
   2046

INCOME STATEMENT

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Revenue growth rate, %
  19.29
  2.00
  2.30
  2.57
  2.81
  3.03
  3.23
  3.41
  3.57
  3.71
  3.84
  3.95
  4.06
  4.15
  4.24
  4.31
  4.38
  4.44
  4.50
  4.55
  4.59
  4.64
  4.67
  4.70
  4.73
  4.76
  4.78
  4.81
  4.83
  4.84
  4.86
Revenue, $m
  3,562
  3,633
  3,717
  3,812
  3,920
  4,038
  4,169
  4,311
  4,464
  4,630
  4,808
  4,998
  5,201
  5,417
  5,646
  5,890
  6,148
  6,421
  6,710
  7,015
  7,338
  7,678
  8,036
  8,414
  8,813
  9,232
  9,674
  10,139
  10,628
  11,143
  11,684
Variable operating expenses, $m
 
  3,034
  3,095
  3,166
  3,245
  3,332
  3,428
  3,532
  3,646
  3,767
  3,898
  3,678
  3,828
  3,987
  4,156
  4,335
  4,525
  4,726
  4,939
  5,163
  5,401
  5,651
  5,915
  6,193
  6,486
  6,795
  7,120
  7,462
  7,823
  8,201
  8,600
Fixed operating expenses, $m
 
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Total operating expenses, $m
  3,129
  3,034
  3,095
  3,166
  3,245
  3,332
  3,428
  3,532
  3,646
  3,767
  3,898
  3,678
  3,828
  3,987
  4,156
  4,335
  4,525
  4,726
  4,939
  5,163
  5,401
  5,651
  5,915
  6,193
  6,486
  6,795
  7,120
  7,462
  7,823
  8,201
  8,600
Operating income, $m
  434
  599
  621
  647
  675
  706
  741
  778
  819
  863
  909
  1,319
  1,373
  1,430
  1,490
  1,555
  1,623
  1,695
  1,771
  1,852
  1,937
  2,027
  2,121
  2,221
  2,326
  2,437
  2,554
  2,677
  2,806
  2,942
  3,084
EBITDA, $m
  686
  1,055
  1,079
  1,107
  1,138
  1,172
  1,210
  1,252
  1,296
  1,344
  1,396
  1,451
  1,510
  1,573
  1,639
  1,710
  1,785
  1,864
  1,948
  2,037
  2,130
  2,229
  2,333
  2,443
  2,559
  2,680
  2,809
  2,944
  3,086
  3,235
  3,392
Interest expense (income), $m
  89
  102
  105
  108
  112
  116
  121
  126
  132
  139
  145
  152
  160
  168
  177
  187
  196
  207
  218
  230
  242
  255
  269
  284
  299
  315
  332
  350
  369
  389
  410
Earnings before tax, $m
  328
  498
  517
  539
  563
  590
  620
  652
  687
  724
  764
  1,167
  1,213
  1,261
  1,313
  1,368
  1,426
  1,488
  1,553
  1,622
  1,695
  1,771
  1,852
  1,937
  2,027
  2,122
  2,221
  2,326
  2,436
  2,552
  2,674
Tax expense, $m
  120
  134
  140
  145
  152
  159
  167
  176
  185
  195
  206
  315
  327
  341
  355
  369
  385
  402
  419
  438
  458
  478
  500
  523
  547
  573
  600
  628
  658
  689
  722
Net income, $m
  206
  363
  377
  393
  411
  431
  452
  476
  501
  529
  558
  852
  885
  921
  959
  999
  1,041
  1,086
  1,134
  1,184
  1,237
  1,293
  1,352
  1,414
  1,480
  1,549
  1,622
  1,698
  1,779
  1,863
  1,952

BALANCE SHEET

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cash and short-term investments, $m
  44
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Total assets, $m
  6,980
  7,082
  7,245
  7,431
  7,640
  7,872
  8,126
  8,403
  8,703
  9,025
  9,372
  9,742
  10,138
  10,559
  11,006
  11,481
  11,984
  12,517
  13,080
  13,675
  14,303
  14,966
  15,665
  16,402
  17,179
  17,997
  18,858
  19,764
  20,718
  21,721
  22,777
Adjusted assets (=assets-cash), $m
  6,936
  7,082
  7,245
  7,431
  7,640
  7,872
  8,126
  8,403
  8,703
  9,025
  9,372
  9,742
  10,138
  10,559
  11,006
  11,481
  11,984
  12,517
  13,080
  13,675
  14,303
  14,966
  15,665
  16,402
  17,179
  17,997
  18,858
  19,764
  20,718
  21,721
  22,777
Revenue / Adjusted assets
  0.514
  0.513
  0.513
  0.513
  0.513
  0.513
  0.513
  0.513
  0.513
  0.513
  0.513
  0.513
  0.513
  0.513
  0.513
  0.513
  0.513
  0.513
  0.513
  0.513
  0.513
  0.513
  0.513
  0.513
  0.513
  0.513
  0.513
  0.513
  0.513
  0.513
  0.513
Average production assets, $m
  2,548
  2,231
  2,282
  2,341
  2,407
  2,480
  2,560
  2,647
  2,741
  2,843
  2,952
  3,069
  3,193
  3,326
  3,467
  3,616
  3,775
  3,942
  4,120
  4,307
  4,505
  4,714
  4,934
  5,166
  5,411
  5,669
  5,940
  6,225
  6,526
  6,842
  7,174
Working capital, $m
  231
  265
  271
  278
  286
  295
  304
  315
  326
  338
  351
  365
  380
  395
  412
  430
  449
  469
  490
  512
  536
  560
  587
  614
  643
  674
  706
  740
  776
  813
  853
Total debt, $m
  2,950
  2,992
  3,089
  3,200
  3,325
  3,463
  3,614
  3,779
  3,958
  4,150
  4,357
  4,577
  4,813
  5,064
  5,331
  5,614
  5,913
  6,231
  6,567
  6,921
  7,296
  7,691
  8,108
  8,547
  9,010
  9,497
  10,010
  10,550
  11,119
  11,717
  12,346
Total liabilities, $m
  4,174
  4,221
  4,318
  4,429
  4,554
  4,692
  4,843
  5,008
  5,187
  5,379
  5,586
  5,806
  6,042
  6,293
  6,560
  6,843
  7,142
  7,460
  7,796
  8,150
  8,525
  8,920
  9,337
  9,776
  10,239
  10,726
  11,239
  11,779
  12,348
  12,946
  13,575
Total equity, $m
  2,806
  2,861
  2,927
  3,002
  3,087
  3,180
  3,283
  3,395
  3,516
  3,646
  3,786
  3,936
  4,096
  4,266
  4,446
  4,638
  4,842
  5,057
  5,284
  5,525
  5,778
  6,046
  6,329
  6,627
  6,940
  7,271
  7,619
  7,985
  8,370
  8,775
  9,202
Total liabilities and equity, $m
  6,980
  7,082
  7,245
  7,431
  7,641
  7,872
  8,126
  8,403
  8,703
  9,025
  9,372
  9,742
  10,138
  10,559
  11,006
  11,481
  11,984
  12,517
  13,080
  13,675
  14,303
  14,966
  15,666
  16,403
  17,179
  17,997
  18,858
  19,764
  20,718
  21,721
  22,777
Debt-to-equity ratio
  1.051
  1.050
  1.060
  1.070
  1.080
  1.090
  1.100
  1.110
  1.130
  1.140
  1.150
  1.160
  1.180
  1.190
  1.200
  1.210
  1.220
  1.230
  1.240
  1.250
  1.260
  1.270
  1.280
  1.290
  1.300
  1.310
  1.310
  1.320
  1.330
  1.340
  1.340
Adjusted equity ratio
  0.398
  0.404
  0.404
  0.404
  0.404
  0.404
  0.404
  0.404
  0.404
  0.404
  0.404
  0.404
  0.404
  0.404
  0.404
  0.404
  0.404
  0.404
  0.404
  0.404
  0.404
  0.404
  0.404
  0.404
  0.404
  0.404
  0.404
  0.404
  0.404
  0.404
  0.404

CASH FLOW

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Net income, $m
  206
  363
  377
  393
  411
  431
  452
  476
  501
  529
  558
  852
  885
  921
  959
  999
  1,041
  1,086
  1,134
  1,184
  1,237
  1,293
  1,352
  1,414
  1,480
  1,549
  1,622
  1,698
  1,779
  1,863
  1,952
Depreciation, amort., depletion, $m
  252
  455
  458
  460
  463
  466
  470
  473
  477
  482
  486
  132
  137
  143
  149
  155
  162
  169
  177
  185
  193
  202
  212
  222
  232
  243
  255
  267
  280
  294
  308
Funds from operations, $m
  577
  819
  835
  853
  874
  897
  922
  949
  979
  1,010
  1,044
  984
  1,022
  1,064
  1,107
  1,154
  1,203
  1,255
  1,311
  1,369
  1,431
  1,495
  1,564
  1,636
  1,712
  1,792
  1,877
  1,965
  2,059
  2,157
  2,260
Change in working capital, $m
  30
  5
  6
  7
  8
  9
  10
  10
  11
  12
  13
  14
  15
  16
  17
  18
  19
  20
  21
  22
  24
  25
  26
  28
  29
  31
  32
  34
  36
  38
  40
Cash from operations, $m
  547
  490
  829
  846
  866
  888
  912
  939
  967
  998
  1,031
  970
  1,007
  1,048
  1,091
  1,136
  1,184
  1,236
  1,290
  1,347
  1,407
  1,471
  1,538
  1,609
  1,683
  1,762
  1,844
  1,931
  2,023
  2,119
  2,221
Maintenance CAPEX, $m
  0
  -94
  -96
  -98
  -100
  -103
  -106
  -110
  -114
  -118
  -122
  -127
  -132
  -137
  -143
  -149
  -155
  -162
  -169
  -177
  -185
  -193
  -202
  -212
  -222
  -232
  -243
  -255
  -267
  -280
  -294
New CAPEX, $m
  -136
  -45
  -51
  -59
  -66
  -73
  -80
  -87
  -94
  -102
  -109
  -117
  -125
  -133
  -141
  -150
  -158
  -168
  -177
  -187
  -198
  -209
  -220
  -232
  -245
  -258
  -271
  -285
  -300
  -316
  -332
Cash from investing activities, $m
  -196
  -139
  -147
  -157
  -166
  -176
  -186
  -197
  -208
  -220
  -231
  -244
  -257
  -270
  -284
  -299
  -313
  -330
  -346
  -364
  -383
  -402
  -422
  -444
  -467
  -490
  -514
  -540
  -567
  -596
  -626
Free cash flow, $m
  351
  351
  682
  690
  700
  712
  726
  742
  759
  779
  800
  726
  751
  778
  807
  838
  871
  906
  943
  982
  1,024
  1,068
  1,115
  1,165
  1,217
  1,272
  1,330
  1,391
  1,455
  1,523
  1,595
Issuance/(repayment) of debt, $m
  -281
  85
  97
  111
  125
  138
  151
  165
  179
  192
  206
  221
  236
  251
  267
  283
  300
  317
  336
  355
  374
  395
  417
  439
  463
  487
  513
  540
  568
  598
  629
Issuance/(repurchase) of shares, $m
  -34
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash from financing (excl. dividends), $m  
  -324
  85
  97
  111
  125
  138
  151
  165
  179
  192
  206
  221
  236
  251
  267
  283
  300
  317
  336
  355
  374
  395
  417
  439
  463
  487
  513
  540
  568
  598
  629
Total cash flow (excl. dividends), $m
  28
  436
  779
  801
  824
  850
  877
  907
  938
  971
  1,007
  947
  987
  1,029
  1,074
  1,121
  1,171
  1,223
  1,279
  1,337
  1,399
  1,464
  1,532
  1,604
  1,680
  1,759
  1,843
  1,931
  2,024
  2,121
  2,224
Retained Cash Flow (-), $m
  -76
  -56
  -66
  -75
  -84
  -94
  -103
  -112
  -121
  -130
  -140
  -150
  -160
  -170
  -181
  -192
  -203
  -215
  -228
  -240
  -254
  -268
  -282
  -298
  -314
  -330
  -348
  -366
  -385
  -405
  -426
Prev. year cash balance distribution, $m
 
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash flow adjustment, $m
 
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash available for distribution, $m
 
  380
  713
  725
  740
  756
  775
  795
  817
  841
  867
  797
  827
  859
  893
  929
  967
  1,008
  1,051
  1,097
  1,145
  1,196
  1,249
  1,306
  1,366
  1,429
  1,495
  1,565
  1,638
  1,716
  1,797
Discount rate, %
 
  8.20
  8.61
  9.04
  9.49
  9.97
  10.47
  10.99
  11.54
  12.12
  12.72
  13.36
  14.02
  14.73
  15.46
  16.24
  17.05
  17.90
  18.79
  19.73
  20.72
  21.76
  22.84
  23.99
  25.19
  26.45
  27.77
  29.16
  30.61
  32.15
  33.75
PV of cash for distribution, $m
 
  351
  604
  560
  515
  470
  426
  383
  341
  300
  262
  201
  171
  144
  119
  97
  78
  61
  47
  36
  26
  19
  14
  9
  6
  4
  3
  2
  1
  1
  0
Current shareholders' claim on cash, %
  100
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0

Stericycle, Inc., together with its subsidiaries, provides regulated and compliance solutions to the healthcare, retail, and commercial businesses in the United States and internationally. The company collects and processes regulated and specialized waste for disposal services, as well as collects personal and confidential information for secure destruction. It offers regulated solutions for medical waste disposal, pharmaceutical waste disposal, and hazardous waste management; sustainability solutions for expired or unused inventory; and secures information destruction of documents and e-media. The company’s compliance solutions comprise Steri-Safe and clinical services programs for training and consulting; inbound/outbound communications; data reporting; and other regulatory compliance services. It also provides reusable sharps disposal management services, integrated waste stream solutions program, and regulated recall and returns management services for expired or recalled products. The company serves healthcare businesses, including hospitals, physician and dental practices, outpatient clinics, and long-term care facilities; retailers and manufacturers; financial and professional service providers; governmental entities; and other businesses. Stericycle, Inc. was founded in 1989 and is headquartered in Lake Forest, Illinois.

FINANCIAL RATIOS  of  Stericycle (SRCL)

Valuation Ratios
P/E Ratio 31.8
Price to Sales 1.8
Price to Book 2.3
Price to Tangible Book
Price to Cash Flow 12
Price to Free Cash Flow 15.9
Growth Rates
Sales Growth Rate 19.3%
Sales - 3 Yr. Growth Rate %
EPS Growth Rate %
EPS - 3 Yr. Growth Rate %
Capital Spending Gr. Rate 18.3%
Cap. Spend. - 3 Yr. Gr. Rate 13.3%
Financial Strength
Quick Ratio 1
Current Ratio 0.1
LT Debt to Equity 102.5%
Total Debt to Equity 105.1%
Interest Coverage 5
Management Effectiveness
Return On Assets 3.7%
Ret/ On Assets - 3 Yr. Avg. 6%
Return On Total Capital 3.5%
Ret/ On T. Cap. - 3 Yr. Avg. 6.3%
Return On Equity 7.4%
Return On Equity - 3 Yr. Avg. 12.3%
Asset Turnover 0.5
Profitability Ratios
Gross Margin 42.2%
Gross Margin - 3 Yr. Avg. 42.5%
EBITDA Margin 18.8%
EBITDA Margin - 3 Yr. Avg. 21.5%
Operating Margin 12.2%
Oper. Margin - 3 Yr. Avg. 16.8%
Pre-Tax Margin 9.2%
Pre-Tax Margin - 3 Yr. Avg. 14%
Net Profit Margin 5.8%
Net Profit Margin - 3 Yr. Avg. 9.2%
Effective Tax Rate 36.6%
Eff/ Tax Rate - 3 Yr. Avg. 34.7%
Payout Ratio 18.9%

SRCL stock valuation input parameters

Revenue. Company's revenue (or sales) is always the starting point of any cash flow forecast. In the SRCL stock intrinsic value calculation we used $3562 million for the last fiscal year's total revenue generated by Stericycle. The default revenue input number comes from 2016 income statement of Stericycle. You may change it if you feel that it should be adjusted for some unusual circumstances that are not expected to be repeated in the future or if you already know (from interim financial statements, for example) that this year's revenue is going to be quite different.

Revenue growth rate. Forecasted future revenue growth rate is the most important input parameter for the intrinsic value calculation. Unlike other input parameters that are reasonably expected to be in line with their historic averages or their historic trends, the revenue growth rate by and large is a wild card: nobody really knows what the company's revenue will be in the future. Of course, the level of unpredictability is different for different industries (utility companies being the most predictable and, thus, less risky).
    We use three input parameters to forecast the revenue growth rate in our SRCL stock valuation model: a) initial revenue growth rate of 2% whose default value is the revenue growth rate in the most recent quarter compared to the quarterly revenue a year ago; b) terminal revenue growth rate of 5% whose default value is chosen to be close to the average nominal (i.e. not adjusted for inflation) GDP growth rate; and c) revenue decline factor of 0.9, which stipulates that revenue growth rate in each forecasted year will be equal to the difference of the revenue growth rate in the preceding year and the terminal revenue growth rate multiplied by this revenue decline factor (with the passage of time the revenue growth rate will be approaching the terminal revenue growth rate, but not quite reaching it - though the difference could be infinitesimally small).
    At the revenue decline factor of 1, the future revenue growth rate is forecasted to be constant and equal to the initial revenue growth rate. The smaller the revenue decline factor, the faster the revenue growth rate will approach the terminal revenue growth.

Discount rate. The discount rate is used for determining the present value of future cash flows: future cash flows are "discounted" as at normal conditions (that translate into positive expected return on investment) one dollar today is worth more than the same dollar in the future. Unlike all other valuation models, we use variable discount rate, i.e. it increases for each consecutive year. This is done to account for higher risk of cash flows coming in further in the future.
    The initial discount rate of 8.2%, whose default value for SRCL is calculated based on our internal credit rating of Stericycle, is applied to the cash flow expected to be received a year from now (well, actually, to be precise, in the financial year following the base year - the last year for which we have financial statements). For each consecutive year the discount rate is multiplied by the discount rate multiplier of 1.05, e.i. each year it increases by 5%. Feel free to change this number to correspond to your level of risk assessment of Stericycle.
    By the way, it is easy to set the discount rate to be constant (this would make comparison with other valuation models easier): just set the discount rate multiplier equal to 1 and chose the magnitude of the initial discount rate to your liking.

Variable cost ratio is the ratio of variable costs (i.e. costs that fluctuate with fluctuation of the volume of production) to the revenue expressed as a percentage. In the calculation of intrinsic value of SRCL stock the variable cost ratio is equal to 83.7%.

Fixed operating expenses is just that - expenses that are not dependant on the volume of production. They are set to $0 million in the base year in the intrinsic value calculation for SRCL stock. These expenses increase with the level of inflation in subsequent years.

Interest rate on debt is the average all-in rate of interest paid by the company on its debt. It is set at 3.5% for Stericycle.

Corporate tax rate of 27% is the nominal tax rate for Stericycle. In reality, companies find ways to pay much less taxes than that or not to pay them at all.

Cash flow adjustment could be used for any adjustment the investor deems necessary. Most commonly we use this field to account for stock options-related effects in excess of what is reported on the company's income statement. The cash flow adjustment is expressed as a percentage of the revenue, and in the current valuation of the SRCL stock is equal to 0%.

Production assets are the company's assets used for manufacturing products or provision of services. In the valuation model input table they are expressed as a percentage of revenue and for SRCL are equal to 61.4%.

Life of production assets of 23.3 years is the average useful life of capital assets used in Stericycle operations. It is used to calculate yearly capital expenditures needed to keep these assets in good order - we call it the maintenance CAPEX.

Working capital is the difference between the company's current assets and liabilities. In the model we use the ratio of working capital to revenue, which for SRCL is equal to 7.3%. A negative number means that the company is apt at using financial resources of its suppliers and customers; a large positive number, on the other hand, means that it either provides in-kind financing to others or is not good at managing its inventories.

Book value of equity - $2805 million for Stericycle - is used in calculation of the "floor" for intrinsic valuation based on the discounted cash flow (DCF) method. Even if the prospects are very bad for a company, its assets could always be sold now for their current fair market value.

Shares outstanding of 84.584 million for Stericycle is needed to calculate the intrinsic value of one share.

Market capitalization is used here only for reference purposes and as a quick check that the share price and the number of shares outstanding numbers are correct - something especially to be cognizant about at stock splits. So, the market capitalization of Stericycle at the current share price and the inputted number of shares is $6.5 billion.


Premium access subscription - $499/yr

please register and log in before paying
RELATED COMPANIES Price Int.Val. Rating
SMED Sharps Complia 4.20 prem.  prem.
WM Waste Manageme 73.43 prem.  prem.
CLH Clean Harbors 53.39 prem.  prem.
ECOL US Ecology 49.75 prem.  prem.

COMPANY NEWS

▶ ETFs with exposure to Stericycle, Inc. : June 15, 2017   [Jun-15-17 03:22PM  Capital Cube]
▶ Stericycle to Present at Investor Conference in June   [May-23-17 05:30PM  GlobeNewswire]
▶ Stericycle tops Street 1Q forecasts   [May-04-17 04:12PM  Associated Press]
▶ ETFs with exposure to Stericycle, Inc. : April 17, 2017   [Apr-17-17 01:07PM  Capital Cube]
▶ Stericycle Setting Up for a Breakout   [Apr-13-17 03:17PM  TheStreet.com]
▶ Stericycle to Participate in Two Investor Events in May   [Apr-12-17 04:02PM  GlobeNewswire]
▶ ETFs with exposure to Stericycle, Inc. : April 5, 2017   [Apr-05-17 05:30PM  Capital Cube]
▶ 3 Profitable Healthcare Services Firms at Good Prices   [Mar-10-17 06:00AM  Morningstar]
▶ Goldman Sachs Relents: Stericycle Upgraded to Neutral   [Mar-07-17 12:33PM  Motley Fool]
▶ Stericycle Statement on Class Certification   [02:23PM  GlobeNewswire]
▶ The Hot Stock: Stericycle Jumps 7.7%   [Feb-16-17 04:36PM  at Barrons.com]
▶ Why Stericycle Stock Jumped 12% on Thursday   [01:05PM  at Motley Fool]
▶ 3 Stocks the Smartest Investors are Buying Right Now   [Dec-20-16 07:36AM  at Motley Fool]
▶ 10 Biggest Stock Market Flops of 2016   [Dec-16-16 10:10AM  at Kiplinger]
▶ Austin's biggest public company loses spot on Nasdaq-100 index   [Dec-14-16 09:35AM  at bizjournals.com]
▶ Changing Healthcare Landscape Benefits Stericycle   [Dec-12-16 07:00AM  at Morningstar]
▶ Here is What Hedge Funds Think About Stericycle Inc (SRCL)   [Nov-30-16 10:37AM  at Insider Monkey]
▶ 3 Takeaways From Stericycle's Q3 Earnings   [Nov-07-16 12:24PM  at Motley Fool]
▶ Stericycle to Present at NASDAQ Conference in November   [Nov-01-16 06:12PM  GlobeNewswire]
Stock chart of SRCL Financial statements of SRCL Annual reports of SRCL
Valuation of Stocks

The paper VALUATION OF STOCKS: The Quest for Intrinsic Value provides a detailed description of our valuation model and discloses the calculation algorithm.

FREE DOWNLOAD
Follow us on:   twitter   twitter   twitter   twitter

VALUATION THEORY       ASSET ALLOCATION

About X-FIN       Site news       Privacy policy       Terms of use       FAQ

Copyright © X-FIN.com 2005-2017. All rigths reserved.